Bringing the Oncology Community Together

Dr. Parsa on a Trial Analyzing G-200 for Glioblastoma

Andrew T. Parsa MD, PhD
Published Online: Tuesday, July 2, 2013
Andrew T. Parsa MD, PhD, Associate Professor in Residence of Neurological Surgery, University of California, San Francisco, describes the design of a trial analyzing prophage G-200 vaccine for recurrent glioblastoma multiforme.

Prophage G-200 is an autologous, patient-specific vaccine used to provoke an immune response in patients with recurrent glioblastoma multiforme. This ongoing phase II study, sponsored by the Alliance for Clinical Trials in Oncology, a cooperative group of the National Cancer Institute, was designed so that patients who have recurrent glioblastoma undergo surgical resection and have confirmation of their diagnosis. Then, the resected tissue is converted into the vaccine, which is held by researchers.

Patients in the trial are randomized to one of three arms: bevacizumab alone, the current standard of care in this disease, bevacizumab in combination with the vaccine, or the vaccine followed by bevacizumab. The study looks to answer the question of whether prophage G-200 can facilitate long term overall survival.

Related Articles
The Role of Radiation in the Management of Brain Metastases
In this review, the role of radiotherapy in the management of brain metastases is considered from a historical perspective, in the context of other treatment modalities, and with regard to different radiotherapy techniques.
Study Suggests IMRT Improves Survival in Head and Neck Cancer
Intensity-modulated radiation therapy (IMRT) improved survival and reduced toxicities compared with conventional radiation treatment in patients with head and neck cancer, according to a recent database analysis.
Dendritic Vaccine Improves Survival in Recurrent Glioblastoma
A personalized vaccine being tested as a therapy for recurrent glioblastoma multiforme (GBM) improved patient survival compared with standard treatments
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.